Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Assets Average (2021 - 2025)

Vivos Therapeutics (VVOS) has disclosed Assets Average for 5 consecutive years, with $25.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets Average rose 65.69% to $25.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $25.8 million, a 65.69% increase, with the full-year FY2024 number at $13.0 million, up 6.4% from a year prior.
  • Assets Average was $25.8 million for Q3 2025 at Vivos Therapeutics, up from $18.7 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $43.6 million in Q3 2021 to a low of $10.5 million in Q4 2023.
  • A 5-year average of $21.1 million and a median of $16.1 million in 2022 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: plummeted 57.01% in 2022, then soared 65.69% in 2025.
  • Vivos Therapeutics' Assets Average stood at $37.4 million in 2021, then crashed by 57.01% to $16.1 million in 2022, then tumbled by 34.47% to $10.5 million in 2023, then skyrocketed by 45.54% to $15.3 million in 2024, then surged by 68.71% to $25.8 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Assets Average are $25.8 million (Q3 2025), $18.7 million (Q2 2025), and $13.3 million (Q1 2025).